NeOnc Technologies (NTHI) vs OKYO Pharma (OKYO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OKYO Pharma (OKYO) has outperformed NeOnc Technologies (NTHI) over the past year, losing 32.4% versus a loss of 76.8%. NeOnc Technologies is the larger company by market cap ($80.1 million vs $74.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTHI | OKYO |
|---|---|---|
| Share price | $2.78 | $1.42 |
| Market cap | $80.08M | $74.52M |
| 1-day change | +9.88% | +2.16% |
| YTD return | -66.38% | -31.40% |
| 1-year return | -76.79% | -32.38% |
| EPS (TTM) | $-2.34 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.09 | $3.20 |
| 52-week low | $2.50 | $1.27 |
| Distance from 52-week high | -77.01% | -55.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +511.51% | +486.62% |
| Average volume | 195.17K | 93.79K |
| Shares outstanding | 28.81M | 52.48M |
| Employees | 5 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OKYO has outperformed NTHI by 44.4 percentage points over the past year.
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About OKYO Pharma
OKYO stock →OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
NTHI vs OKYO FAQ
Which is bigger, NeOnc Technologies or OKYO Pharma?
NeOnc Technologies (NTHI) is larger, with a market capitalization of $80.08M compared with $74.52M for OKYO Pharma (OKYO).
Which stock has performed better over the past year, NTHI or OKYO?
OKYO returned -32.38% over the past 12 months, compared with -76.79% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are NeOnc Technologies and OKYO Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for NeOnc Technologies and Biotechnology: Biological Products (No Diagnostic Substances) for OKYO Pharma.